event-driven endpoint Obstructive Sleep Apnea Status: Phase 3 Planned Focus: OSA severity reduction (apnea-hypopnea index) with CagriSema-induced weight loss Population: Adults with moderate-severe OSA and obesity Timeline: Expected enrollment 2024-2025 NASH/MAFLD Status: Phase 2 Ongoing Focus: Hepatic steatosis, inflammation, and fibrosis improvement Population: Adults with biopsy-confirmed NASH/MAFLD Timeline: Results expected 2025 Heart Failure with Preserved EF Status: Preclinical Planning Focus: HFpEF outcomes in obese patients following substantial weight loss Rationale: Obesity-HFpEF phenotype may benefit from profound weight reduction Timeline: Early development phase Pediatric Obesity Status: Phase 2 Planning Focus: Safety, tolerability, and efficacy in adolescents (12-18 years) Population: Adolescents with obesity (BMI 95th percentile) Timeline: Expected initiation 2025 Oral Formulation Development Status: Preclinical Focus: Oral bioavailability enhancement for cagrilintide using absorption enhancers Rationale: Oral delivery could improve accessibility and adherence Timeline: Research phase
It plays a central role in detoxification, immune function, and cellular protection
The association of interleukin-1alpha and interleukin-1beta polymorphisms with the risk of Graves' disease in a case-control study and meta-analysis
Vaughn DJ, Bellmunt J, and Fradet Y, et al (2018) Health-related quality-of-life analysis from KEYNOTE-045: a phase III study of pembrolizumab versus chemotherapy for previously treated advanced urothelial cancer J Clin Oncol 36 (16) 15791587 PMID: 29590008 10
Improves elasticity
Pine Bark Extract Citrus Bioflavonoids Zinc Gluta Glow Complex Giffarine Gluta Glow Complex : - 250.0
